Baseline characteristics
| . | Diabetic subjects . | Nondiabetic subjects . |
|---|---|---|
| n | 127 | 5,118 |
| Age (years) | 55.6 ± 5.7 | 55.3 ± 5.5 |
| BMI (kg/m2) | 27.8 ± 3.7 | 25.9 ± 3.1 |
| Alcohol (units/week) | 11 ± 15 | 11 ± 13 |
| Smoking (Y/N) | 58 (46) | 2,222 (43) |
| Pravastatin therapy | 52 (41) | 2,579 (50) |
| Systolic blood pressure (mmHg) | 138 ± 17 | 135 ± 17 |
| Diastolic blood pressure (mmHg) | 85 ± 10 | 84 ± 10 |
| Hypertension (Y/N) | 34 (27) | 793 (15) |
| Ln(triglyceride) [ln(mmol/l)] | 0.78 ± 0.39 | 0.51 ± 0.40 |
| Total cholesterol (mmol/l) | 7.18 ± 0.61 | 7.02 ± 0.58 |
| HDL cholesterol (mmol/l) | 1.04 ± 0.20 | 1.14 ± 0.24 |
| Total cholesterol–to–HDL cholesterol ratio | 7.15 ± 1.48 | 6.41 ± 1.36 |
| Glucose (mmol/l) | 5.48 ± 0.70 | 4.69 ± 0.49 |
| Ln(WCC) [ln(109 cells/l)] | 1.94 ± 0.26 | 1.84 ± 0.27 |
| Ln(sensitive CRP) [ln(mg/l)] | 1.05 ± 0.90 | 0.53 ± 1.08 |
| . | Diabetic subjects . | Nondiabetic subjects . |
|---|---|---|
| n | 127 | 5,118 |
| Age (years) | 55.6 ± 5.7 | 55.3 ± 5.5 |
| BMI (kg/m2) | 27.8 ± 3.7 | 25.9 ± 3.1 |
| Alcohol (units/week) | 11 ± 15 | 11 ± 13 |
| Smoking (Y/N) | 58 (46) | 2,222 (43) |
| Pravastatin therapy | 52 (41) | 2,579 (50) |
| Systolic blood pressure (mmHg) | 138 ± 17 | 135 ± 17 |
| Diastolic blood pressure (mmHg) | 85 ± 10 | 84 ± 10 |
| Hypertension (Y/N) | 34 (27) | 793 (15) |
| Ln(triglyceride) [ln(mmol/l)] | 0.78 ± 0.39 | 0.51 ± 0.40 |
| Total cholesterol (mmol/l) | 7.18 ± 0.61 | 7.02 ± 0.58 |
| HDL cholesterol (mmol/l) | 1.04 ± 0.20 | 1.14 ± 0.24 |
| Total cholesterol–to–HDL cholesterol ratio | 7.15 ± 1.48 | 6.41 ± 1.36 |
| Glucose (mmol/l) | 5.48 ± 0.70 | 4.69 ± 0.49 |
| Ln(WCC) [ln(109 cells/l)] | 1.94 ± 0.26 | 1.84 ± 0.27 |
| Ln(sensitive CRP) [ln(mg/l)] | 1.05 ± 0.90 | 0.53 ± 1.08 |
Data for continuous measurements are means ± SD, and for categorical measurements, n (%). Baseline characteristics of subjects who had at least two post-randomization measurements of glucose, were not self-reported diabetic patients at baseline and did not have a fasting glucose at baseline ≥7.0 mmol/l, and had baseline plasma available for CRP measurements. Ln, natural logarithm.